Biomarker Lab

Committed to helping our customers identify the right strategy for each development phase

**Learn more about the biomarker lab below or advance to the next page to move on to the central lab**

Our scientists have successfully completed 750+ biomarker studies in the last five years.

PPD Laboratory Services takes a collaborative cross-functional approach to each project in order to provide the flexibility needed to develop customized solutions. Our dedicated biomarker laboratories across the globe work closely with customers to shape biomarker strategy and drive projects to completion even where uncertainty exists.Our biomarker lab is equipped with depth and breadth of industry experience Biomarkers reveal critical insights about your drug and its potential for commercial success, our biomarker lab has supported more than 750 programs in the past five years. Our capabilities include:

Flow cytometry

Cell-based assays

Ligand-binding assays

Immunohistochemistry

LC-MS

Molecular assays and genomics

PPD® Laboratory services takes a collaborative cross-functional approach to each project in order to provide the flexibility needed to develop customized solutions for our customers.

An integrated approach to biomarker development We are committed to helping customers identify the right strategy for each development phase so they can efficiently achieve their end goals Our approach:

Provides flexibility

Leverages the operational experience of PPD Laboratory Services bioanalytical and central labs

Allows the biomarker team to provide a customized development strategy for each project

Enables the biomarker lab to apply a tiered regulatory strategy from fit-for-purpose and GLP to GCLP and CLIA

PPD Laboratory Services has a dedicated biomarker lab integrated into central lab locations across the globe

We customize our solutions to achieve actionable results

Our biomarker experts are in close contact with the various lab locations to ensure integration and a smooth transition of assays and technology during development of the biomarker program.

Take a tour of our molecular genomics suite >